6,062 Shares in Guardant Health, Inc. $GH Acquired by Sanctuary Advisors LLC

Sanctuary Advisors LLC purchased a new position in shares of Guardant Health, Inc. (NASDAQ:GH) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 6,062 shares of the company’s stock, valued at approximately $909,000.

Other hedge funds also recently made changes to their positions in the company. GAMMA Investing LLC increased its holdings in shares of Guardant Health by 14.5% during the 2nd quarter. GAMMA Investing LLC now owns 965 shares of the company’s stock worth $145,000 after buying an additional 122 shares during the last quarter. First Pacific Financial raised its position in shares of Guardant Health by 33.1% in the 1st quarter. First Pacific Financial now owns 559 shares of the company’s stock worth $52,000 after buying an additional 139 shares during the period. Xponance LLC boosted its holdings in Guardant Health by 2.1% in the fourth quarter. Xponance LLC now owns 9,630 shares of the company’s stock valued at $984,000 after acquiring an additional 199 shares during the last quarter. Danske Bank A S boosted its holdings in Guardant Health by 20.0% in the fourth quarter. Danske Bank A S now owns 1,200 shares of the company’s stock valued at $123,000 after acquiring an additional 200 shares during the last quarter. Finally, Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna boosted its holdings in Guardant Health by 1.9% in the fourth quarter. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna now owns 11,000 shares of the company’s stock valued at $1,124,000 after acquiring an additional 200 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Stock Down 4.2%

GH stock opened at $161.50 on Friday. The stock’s 50 day moving average is $157.49 and its two-hundred day moving average is $120.75. Guardant Health, Inc. has a 52-week low of $53.40 and a 52-week high of $176.58. The company has a market capitalization of $21.67 billion, a PE ratio of -46.27 and a beta of 1.60.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.34. The business had revenue of $334.98 million for the quarter, compared to analysts’ expectations of $314.23 million. During the same quarter last year, the company posted ($0.44) earnings per share. The business’s quarterly revenue was up 44.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Guardant Health, Inc. will post -2.98 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on GH shares. Piper Sandler upped their price target on Guardant Health from $135.00 to $193.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. Mizuho lifted their price objective on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Barclays boosted their target price on Guardant Health from $150.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Stephens increased their target price on shares of Guardant Health from $170.00 to $195.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Finally, Stifel Nicolaus raised their price target on shares of Guardant Health from $130.00 to $180.00 and gave the company a “buy” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $183.78.

Insider Transactions at Guardant Health

In other Guardant Health news, insider Chris Freeman sold 63,605 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $169.58, for a total transaction of $10,786,135.90. Following the transaction, the insider directly owned 65,374 shares in the company, valued at $11,086,122.92. This represents a 49.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ian T. Clark sold 14,180 shares of the firm’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $158.92, for a total transaction of $2,253,485.60. Following the transaction, the director directly owned 2,975 shares of the company’s stock, valued at approximately $472,787. This represents a 82.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 548,318 shares of company stock valued at $82,501,873 over the last ninety days. 5.60% of the stock is currently owned by corporate insiders.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.